Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Aug 2022. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5091385017 | Human epidermal growth factor receptor 2 inhibitor therapy | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 5091386016 | Human epidermal growth factor receptor 2 targeted therapy | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 5091387013 | Receptor tyrosine-protein kinase erbB-2 inhibitor therapy (procedure) | en | Fully specified name | Active | Only initial character case insensitive | SNOMED CT core module |
| 5091388015 | HER2 (Human epidermal growth factor receptor 2) inhibitor therapy | en | Synonym | Active | Entire term case sensitive | SNOMED CT core module |
| 5091398014 | Receptor tyrosine-protein kinase erbB-2 inhibitor therapy | en | Synonym | Active | Only initial character case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Receptor tyrosine-protein kinase erbB-2 inhibitor therapy | Is a | Drug therapy | true | Inferred relationship | Existential restriction modifier | ||
| Receptor tyrosine-protein kinase erbB-2 inhibitor therapy | Has intent | Therapeutic intent | true | Inferred relationship | Existential restriction modifier | 2 | |
| Receptor tyrosine-protein kinase erbB-2 inhibitor therapy | Method | Administration - action | true | Inferred relationship | Existential restriction modifier | 1 | |
| Receptor tyrosine-protein kinase erbB-2 inhibitor therapy | Direct substance | Substance with human epidermal growth factor receptor 2 inhibitor mechanism of action (substance) | true | Inferred relationship | Existential restriction modifier | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR